Unknown

Dataset Information

0

MTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation.


ABSTRACT: A master coordinator of cell growth, mTORC1 is activated by different metabolic inputs, particularly the metabolism of glutamine (glutaminolysis), to control a vast range of cellular processes, including autophagy. As a well-recognized tumour promoter, inhibitors of mTORC1 such as rapamycin have been approved as anti-cancer agents, but their overall outcome in patients is rather poor. Here we show that mTORC1 also presents tumour suppressor features in conditions of nutrient restrictions. Thus, the activation of mTORC1 by glutaminolysis during nutritional imbalance inhibits autophagy and induces apoptosis in cancer cells. Importantly, rapamycin treatment reactivates autophagy and prevents the mTORC1-mediated apoptosis. We also observe that the ability of mTORC1 to activate apoptosis is mediated by the adaptor protein p62. Thus, the mTORC1-mediated upregulation of p62 during nutrient imbalance induces the binding of p62 to caspase 8 and the subsequent activation of the caspase pathway. Our data highlight the role of autophagy as a survival mechanism upon rapamycin treatment.

SUBMITTER: Villar VH 

PROVIDER: S-EPMC5264013 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation.

Villar Victor H VH   Nguyen Tra Ly TL   Delcroix Vanessa V   Terés Silvia S   Bouchecareilh Marion M   Salin Bénédicte B   Bodineau Clément C   Vacher Pierre P   Priault Muriel M   Soubeyran Pierre P   Durán Raúl V RV  

Nature communications 20170123


A master coordinator of cell growth, mTORC1 is activated by different metabolic inputs, particularly the metabolism of glutamine (glutaminolysis), to control a vast range of cellular processes, including autophagy. As a well-recognized tumour promoter, inhibitors of mTORC1 such as rapamycin have been approved as anti-cancer agents, but their overall outcome in patients is rather poor. Here we show that mTORC1 also presents tumour suppressor features in conditions of nutrient restrictions. Thus,  ...[more]

Similar Datasets

| S-EPMC7969356 | biostudies-literature
| S-EPMC4915159 | biostudies-literature
| S-EPMC4176339 | biostudies-literature
| S-EPMC7531880 | biostudies-literature
| S-EPMC6774112 | biostudies-literature
2024-02-13 | GSE184247 | GEO
2021-11-01 | GSE161073 | GEO
| S-EPMC9809151 | biostudies-literature
2021-02-24 | GSE164011 | GEO
| S-EPMC9566891 | biostudies-literature